Homepage Top Section1

In the DAPA-CKD trial that featured 4,304 adult patients, Farxiga 10mg, when compared to placebo, delivered a statistically significant and clinically meaningful impact on its primary endpoint of

Remsima, which is an infliximab biosimilar, has now been indicated for the treatment of adults having ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Its latest approval

According to Jnana Therapeutics, the small molecule drugs will be developed for targeting the solute carrier (SLC) family of metabolite transporters for regulating cellular metabolism. The Massachusetts-based biotech

AZD1222 was co-invented by Oxford University and its spin-out company Vaccitech. The recombinant adenovirus vaccine, which was licensed by AstraZeneca in May 2020, was tolerated by the participants

The late-stage study of the Covid-19 inactivated vaccine candidate marks the first phase 3 clinical trial for any vaccine candidate being developed in the world against the novel

Nintedanib already secured approval from the US Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) as the first treatment for

The first group of volunteers who were administered the coronavirus vaccine candidate will be discharged this week, reported Sputnik, citing the university’s Institute for Translational Medicine and Biotechnology

More than 20 biopharmaceutical companies have collaborated to establish the AMR Action Fund, which will help focus on medicines that address most resistant bacteria and life-threatening infections. The

The Series B round of Goldfinch Bio was led by Eventide Asset Management. It also included new investors – Wellington Management Company, Ally Bridge Group, Casdin Capital, funds